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Collagen  arthritis  in  rats  is  an  animal  model  of polyarthritis  that  can  be 
produced by an intradermal injection of homologous or heterologous native type 
II collagen emulsified in incomplete Freund's adjuvant (ICFA) 1 (1). The disease, 
which  resembles human  rheumatoid  arthritis  in  many aspects (2),  is  not com- 
pletely understood but appears to be the result of an autoimmune response to 
type II collagen  (3,  4).  It has recently been reported  that  the development of 
arthritis and the immune response to type II collagen are suppressed by pretreat- 
ing the rats with immunosuppressive agents such as cyclophosphamide, azathio- 
prine, and steroids (5-7). 
Cyclosporin A  (CS-A), a  new antilymphocytic drug,  has been described as a 
potent  immunosuppressive  agent.  Several  lines  of evidence  suggest  that  the 
action of CS-A is predominantly or exclusively limited to T cell-mediated immune 
responses (8-1 1). Its usefulness is currently being actively investigated in various 
in vivo and in vitro conditions, and great expectations have been placed on CS- 
A  because its remarkable  immunosuppressive potency is associated with a  very 
low degree of myelotoxicity (12). 
In the present study, we evaluated CS-A for its effectiveness in preventing the 
development of collagen arthritis by treating the rats for the first 14 d with CS- 
A. In an attempt to gain further insight into the mode of action of CS-A, we also 
investigated the effects of CS-A treatment in three different regimens:  (a) only 
during the induction phase of immunity; (b) only during the immediate preclinical 
phase  of arthritis;  (c)  on  the  established  disease.  This  report  describes  some 
preliminary results of CS-A in this animal model of polyarthritis. 
Materials and Methods 
Rats.  Outbred female Sprague-Dawley  rats (Japan Charles  River Breeding Laborato- 
ries,  Kanagawa, Japan),  6-8  wk old and  weighing  130-200 g,  were used.  They were 
housed in groups of five or six in metal cages and fed ad libitum with standard laboratory 
chow and water. 
Collagen Preparation  and Analysis.  Type II collagen  was isolated  and  purified  from 
bovine articular cartilage,  as described by Trentham  et al.  (1). Purity was assessed by 
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Faculty of Medicine, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka,  Japan 812. 
t Abbreviations  used in thispaper:  BSA,  bovine  serum albumin; CS-A, cyclosporin  A; DTH, delayed- 
type hypersensitivity; ICFA, incomplete Freund's adjuvant; PBS, phosphate-buffered  saline. 
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amino acid analysis, which showed 96 residues of hydroxyproline per 1,000 total amino 
acid residues of the collagen preparation. Polyacrylamide gel electrophoresis in sodium 
dodecyl sulfate,  under  conditions  of urea  denaturation  (13),  revealed a  band  pattern 
characteristic  of type II collagen.  Proteoglycan contamination was below the  limits of 
detection by uronic acid assay (14).  The collagen was lyophilized and stored at -20°C. 
Immunization  Procedures.  Lyophilized type II collagen was dissolved in  0.1  M  acetic 
acid at a concentration of 6 mg/ml. The collagen solution was clarified by centrifugation 
(20,000 g, 90 min) and diluted when necessary with 0.1  M acetic acid. Equal volumes of 
collagen solution and ICFA (Difco Laboratories, Inc., Detroit, MI) were emulsified using 
a  homogenizer (Polytron  PT  10-35;  Kinematica,  Lucerne,  Switzerland) and  kept cold 
with an ice bath. A total volume of 1 ml of the cold emulsion was injected intradermally 
at several sites on the back and at 1 or 2 sites into the base of the tail. 
Treatment with CS-A.  CS-A (OL 27-400; Sandoz Ltd., Basel, Switzerland) was provided 
in powder form and dissolved in pure olive oil at concentrations of 5 or  10 mg/ml by 
heating in a water bath to 65°C. It was prepared fresh every 3 d. CS-A was administered 
orally by gastric intubation  under  light ether anesthesia on the  days and at the doses 
indicated in the text. The dose was adjusted according to the daily body weight. Control 
rats, while immunized with the same amount of type II collagen, received oral adminis- 
trations of olive oil alone.  CS-A-treated and  control  rats were handled  identically  for 
administration of the agent and the solvent. 
Assessment of Arthritis.  Rats were examined daily for 4-5 wk after immunization with 
type II collagen to record the day of onset and the severity of arthritis. The lesions of the 
four paws were each graded from 0 to 4 according to increasing extent of periarticular 
erythema  and  swelling  as  well  as joint  deformity,  as  described  previously  (15).  The 
maximum possible score was 16. 
Immune Responses  to Type lI Collagen.  Blood was collected by cardiac puncture under 
light ether anesthesia. Sera were removed, heat inactivated at 56°C for 30 min, and stored 
at -20°C until used. Serum antibodies to type II collagen were measured by the enzyme- 
linked immunoassay technique. The methods used were adapted from those of Voller et 
al. (16).  Briefly, disposable polystyrene cuvettes were coated by incubation with 100 #1 of 
type II collagen solution (25 #g/ml in coating buffer, pH 9.6). After overnight incubation 
at 4°C and washing three times with phosphate-buffered saline (PBS) containing 0.05% 
Tween 20, the remaining protein-binding sites were blocked by the addition of coating 
buffer containing  1%  bovine serum albumin (BSA)  and incubation continued at room 
temperature for 1 h. The cuvettes were washed as described above. Serum was diluted 
with PBS-Tween containing  1% BSA and 100-#1 aliquots of each dilution were placed in 
duplicate or triplicate cuvettes. After incubation at room temperature for 2 h and washing 
with PBS-Tween,  100 #1 of a  1:500 dilution of alkaline phosphatase-conjugated anti-rat 
IgG (Miles Laboratories, Inc., Elkhart, IN) was added and incubation continued at room 
temperature  for  3  h.  Excess conjugate was washed out and  the  amount of conjugate 
specifically bound was determined by adding  100 #1 of p-nitrophenyl phosphate solution 
(1 mg/ml in 10% diethanolamine buffer, pH 9.8). After incubation at room temperature 
for 30 min, the reaction was stopped by adding 20 #1 of 3 N NaOH to each well and the 
reaction  product  was  measured  by absorbance at 410  nm  using an automated device 
(Dynatech  Laboratories,  Inc., Alexandria,  VA).  All  of the  experiments reported  here 
used a single batch of alkaline phosphatase conjugate and included appropriate positive 
and  negative controls.  Antibody  levels were expressed in absorbance values based on 
preliminary studies of serial dilutions  of the  reference samples under  the actual assay 
system. Delayed-type hypersensitivity (DTH) skin testing was performed on day 25,  as 
described by Griffiths et al. (17), and the responses were read at 48 h. 
Statistics.  Continuous variables were analyzed by their group means (Student's t test) 
and dichotomous variables by their proportionate group frequencies (chi-square test). P 
values <0.05 were considered to he statistically significant. KAIBARA ET  AL.  2009 
Results 
Effect of the Immunizing Dose of Type H Collagen on the Production of arthritis.  To 
find the optimal dose of type II collagen for the production of a high incidence 
of arthritis, rats were injected with various doses of type II collagen emulsified 
in ICFA. The results are summarized in Table I.  15 of 30 rats (50%) injected 
with 0.5 mg of type II collagen developed arthritis. When larger doses of type 
II collagen (1.5 mg or more) Were used, 86% of the rats developed arthritis and 
the peak incidence of the disease occurred between 9 and 14 d after immuniza- 
tion. In our hands, consistently 80-90% of the rats developed arthritis when 1.5 
mg of type II collagen in ICFA was injected intradermally not only at several 
sites on the back but also at 1 or 2 sites into the base of the tail. Therefore, in 
the subsequent studies, we routinely used this regimen of immunization. 
Dose-Response  Studies  of  CS-A  on  the  Development  of  Collagen  Arthritis  in 
Rats.  Dose-response  studies  of CS-A  were  carried  out  in  a  14-d  course  of 
treatment in which the rats received daily administration of CS-A or olive oil for 
14  d,  starting  on  the  same  day  as  the  type  II  collagen  immunization.  An 
inflammatory polyarthritis was induced in 12 of 14 rats treated with olive oil for 
14 d. Daily treatment with CS-A in doses of 15 or 25 mg/kg per day for 14 d 
gave complete suppression of arthritis induction during an observation period 
of 4 wk, while a daily dose of 5 mg/kg was without effect (Table II). 
Serum antibody levels to type II collagen were measured on day 21, and DTH 
skin testing was performed on day 25. Olive oil-treated control rats showed high 
antibody levels and strong positive skin test responses to type II collagen, whereas 
very weak or no antibody responses and negative to weak skin test responses to 
type II collagen could be detected in the rats treated with CS-A at doses of 15 
or 25 mg/kg per day. These results indicate that CS-A blocks the helper T  cell 
function necessary for the antibody responses to type II collagen, because CS-A 
does not directly affect B lymphocytes. 
Timing Studies of CS-A Treatment on Collagen Arthritis in Rats.  In the preceding 
section it was demonstrated that CS-A treatment at doses of 15 mg/kg per day 
or more for the first  14  d  suppressed the development of arthritis as well as 
humoral and skin test responses to type II collagen. In this section, we wished to 
see if CS-A given only during the induction phase of immunity or only during 
the immediate preclinical phase of arthritis would have similar effects. Also, the 
TABLE  I 
Effect of the Immunizing Dose of Type II Collagen on the Production of 
Arthritis 
Type II  Incidence  of 
collagen  arthritis* 
Number of rats with polyarthritis 
scoring: 
0  1-5  6-10  11-16 
mg 
0.5  15/s0 (5o%)  15  10  5  0 
1.5  28/33 (85%)  5  15  12  1 
3.0  9]10 (90%)  1  6  3  0 
* Number of rats with  arthritis per number  of rats tested. 2010  EFFECTS  OF  CYCLOSPORIN  A  ON  COLLAGEN  ARTHRITIS 
TABLE  II 
Effect of CS-A Treatment (Days 0-13) on the Development of Collagen Arthritis 
CS-A dose (mg/kg) 
25  15  5 
Olive oil 
Incidence of arthritis  0/14"  0/14"  11/14 (79%)  12/14 (86%) 
Arthritic index*  --  --  4.9 +  0.9  5.5 +  0.8 
Day of onset  4  --  --  11.0 _+ 0.6  10.4 _+ 0.4 
Antibody level  !  0.014  0.01"*  0.66 +  0.13  0.90 -+ 0.14 
DTH skin reaction  ~  3.3 ±  0.6  H  "  3.2 +  0.9 !1  5.4 +  0.5  5.7 -+ 0.4 
* P  <  0.002 vs. the oil group. 
* Expressed as the mean of maximum arthritic indices _+ SEM. 
4 Based on arthritic rats only (mean _+ SEM). 
n Antibody levels to type II  collagen were measured using enzyme-linked immunoassay system on 
day  21  and  expressed  in  absorbance  values at  410  nm  (mean  ±  SEM).  A  serum  dilution  of 
1:30,000 was used for detection of antibodies. 
P  <  0.001  vs. the oil group. 
** P  <  0.005 vs. the oil group. 
** On day 25; expressed as the mean _+ SEM diameter of induration (mm). 
P  <  0.01  vs. the oil group. 
l! p  <  0.02  vs. the oil  group.  For all  the other parameters depicted  in  this table,  the differences 
between the groups were not significant. 
TABLE  III 
Effect of CS-A Treatment (Days 0-6) on the Development of Collagen Arthritis* 
CS-A dose (mg/kg) 
25  15 
Olive oil 
Incidence of arthritis  2/16 (13%)*  4/18 (22%)*  14/15 (93%) 
Arthritic index  0.3 _  0.24  1.0 _+ 0.54  6.1 _  0.8 
Day of onset  13.5_+ 2.5  15.0+  2.8  11.4_+ 1.0 
Antibody level  0.15 +  0.044  0.22 _+ 0.084  1.04 __ 0.10 
DTH  skin reaction  3.6 +  0.41  4.2 4- 0.41  5.7 _+ 0.2 
* Parameters and units are identical to those described in Table II. 
* P  <  0.002 vs. the oil group. 
Op<  0.001  vs. the oil group. 
I P  <  0.005 vs. the oil group. 
I p  <  0.02 vs. the oil group.  For all the other parameters depicted  in this table,  the 
differences between the groups were not significant. 
response  of the  established  disease  to  CS-A  treatment  was  studied.  In  other 
words,  groups  of rats  were treated  with  CS-A or solvent for 7-d periods only 
starting  on  days  0,  7,  and  14.  The  results  are  given  in  Tables  III-V.  The 
development of arthritis was suppressed only if CS-A treatment was started on 
the same  day as type II collagen immunization.  The results showed that a  7-d 
course was nearly as effective as a  14-d course. When CS-A treatment was started 
7 d  after immunization, all of the rats developed arthritis, though the incidence 
and onset day of arthritis in CS-A-treated rats  were not significantly different 
from  those  of olive oil-treated control  rats,  statistically.  However, the  clinical 
signs  of arthritis  in  CS-A-treated  rats  were  significantly  enhanced  in  a  dose- 
dependent  manner  (Table  IV).  In  particular,  forepaw  involvement was  more 
frequently observed in CS-A-treated rats.  13 of 19 arthritic rats treated with a 
50 mg/kg per day dose of CS-A developed swelling and inflammation of digits KAIBARA  ET  AL. 
TABLE  IV 
Effect of CS-A Treatment (Days 7-13) on Collagen Arthritis 
2011 
CS-A dose (mg]kg) 
50  25  15 
Olive oil 
Incidence of arthritis  19/19  20/20  8/8  14/16 (88%) 
Arthritic index  9.7 ±  0.7*  9.3 +  1.0'  7.6 _+ 1.1  5.8 ±  0.7 
Day of onset  9.9 ±  0.3  9.8 ±  0.3  11.5 ±  1.0  10.1 ±  0.4 
Antibody level 
Day 15  0,47 ±  0.06  !  0.57 ±  0.07 i  ND  ~  0.84 ±  0.08 
Day21  0.51  ±0.07*  0.72 ±  0.08 t  0.59 ±  0,111  1.03±0.12 
DTH skin reaction  7.0 ±  0.4*  7.0 ±  0.2*  7.1  ±  0,41  5.5 ±  0.4 
Parameters and units are identical to those described in Table II. 
* P  <  0.001  vs. the oil group. 
* P  <  0.02 vs. the oil group. 
g P  <  0.005 vs. the oil group. 
m  p  <  0.05  vs.  the oil  group.  For  all  the other  parameters depicted  in  this table,  the differences 
between the groups were not significant. 
Not done. 
TABLE  V 
Effect of CS-A Treatment (Days 14-20) on the Established Lesions of 
Collagen Arthritis 
CS-A dose (mg/kg) 
50  25 
Olive oil 
Number of rats tested  14  15  15 
Arthritic index  10.4 ±  1.1 *  9.3 ±  1.1  7.5 ±  0.7 
Antibody level  0.88 ±  0.11  0.96 __. 0.11  1.07 ±  0.12 
DTH  skin reaction  7.6 ±  0.4*  7.5 _  0.4*  5.3 ±  0.6 
Parameters and units are identical to those described in Table II. 
* P  <  0.05 vs. the oil group. 
* P  <  0.02 vs. the oil group. For all the other parameters depicted in this table, 
the differences between the groups were not significant, 
and wrists, grossly evidenced within 6 d  of disease onset. In contrast, only 1 of 
14 arthritic rats in the control group developed forepaw inflammation during 
an observation period of 4 wk. This enhancement of the disease was maintained 
for the period of CS-A dosing and as long as 7 d  after withdrawal of CS-A. In 
addition, this regimen caused an augmentation of DTH skin reactions to type II 
collagen and concomitantly suppressed antibody responses measured on days 15 
and 21. 
In  the  next  experiment,  the  response  of the  established  disease  to  CS-A 
treatment was studied. Groups of 16 rats were immunized with type II collagen 
on day 0. One or 2 animals in each group did not develop arthritis by day 14 
and were removed from the experiment. The remaining 14 or 15 rats per group 
were then given CS-A in doses of 25 or 50 mg/kg per day or olive oil alone from 
day 14-20.  The results are shown in Table V. CS-A treatment from day 14 to 
20 also caused a dose-related enhancement of the disease and an augmentation 
of DTH skin reactions without affecting antibody responses. 2012  EFFECTS  OF  CYCLOSPORIN  A  ON  COLLAGEN  ARTHRITIS 
Discussion 
Although the precise mechanism of action of CS-A is not completely under- 
stood, current evidence suggests that it may exert its action on the early events 
of T  lymphocyte proliferation by interfering with the production and/or release 
of interleukin  2,  and  possibly also  by abrogating  the responses of T  cells to 
interleukin 2 (18-21). The main target for the action of CS-A appears to be the 
helper T  cells (8-11, 21-23). 
The results described in this report clearly demonstrate that CS-A completely 
prevented the development of arthritis in type II collagen-immunized rats when 
the agent was given prophylactically. They also demonstrate the suppression of 
anti-type II  collagen antibody formations and  DTH  skin  reactions to  type II 
collagen. These results accord with the data obtained in several in vivo systems 
(8, 9,  12, 23), indicating that CS-A has a suppressive effect on various aspects of 
T  cell-mediated immune responses, possibly by interfering with helper T  cells. 
Since evidence was presented that CS-A impairs T cell functions by interfering 
with an early stage of antigenic triggering (8-1 I), almost invariably, treatment 
with CS-A has been started at the beginning or soon after the antigenic stimula- 
tion  both  in  vitro  and  in  vivo.  However,  in  a  model  such  as  experimental 
autoimmune uveitis, treatment with CS-A starting only during the effector phase 
proved to be successful (24).  Moreover, therapeutic treatment with CS-A dem- 
onstrated a  pronounced reduction of the inflammatory symptoms in adjuvant 
arthritis  (8)  and an  impressive improvement of the conditon of experimental 
allergic encephalomyelitis in the rat (25). 
Based on these findings, one might expect a therapeutic effect of CS-A on an 
ongoing or established disease of collagen arthritis  in  rats.  Therefore, in  the 
present study, we also investigated the effects of CS-A on collagen arthritis in 
the three experimental protocols; i.e., the time of CS-A administration was varied 
in respect to the time of immunization. In the first, CS-A was given only during 
the induction phase of immunity, which proved to be successful. It was confirmed 
that a 7-d course of CS-A treatment was nearly as effective as a  14-d course. 
In the second experiment, CS-A treatment was started only during the imme- 
diate preclinical phase of arthritis.  The results of this experiment were unex- 
pected. In contrast to the olive oil-treated control rats, CS-A-treated rats showed 
a marked enhancement of the disease in a dose-dependent manner. In addition, 
this regimen caused an augmentation of DTH skin reactions, and concomitantly 
depressed antibody responses. These results are in marked contrast to those seen 
with experimental autoimmune uveitis in the rat, where CS-A treatment begun 
7 d after immunization efficiently  prevented the disease process (24). The reasons 
for this apparent discrepancy are unclear, but the enhancing effect of CS-A in 
the present experiment seems to be operational only in  immunologically trig- 
gered inflammatory responses. A possible explanation is that CS-A treatment in 
a  late stage of immunization inhibited a  clonal  expansion of a  population  of 
suppressor T  cells while permitting the activation of helper T  cells and caused 
severe arthritis. In support of this, recent data from Palacios (20) show that CS- 
A inhibits the generation of suppressor T  cells in an autologous mixed lympho- 
cyte culture system. Further in  vivo circumstantial evidence was presented by 
Thomson et al. (26), in which CS-A administration to guinea pigs on days 0-4 KAIBARA  ET  AL.  2013 
after  ovalbumin  immunization  caused  dose-related potentiation  of  14-d  skin 
responses.  Wick  et al.  (27)  demonstrated that  CS-A  administration to  Obese 
strain chicken embryos resulted in the development of significantly more severe 
spontaneous autoimmune thyroiditis and suggested a suppressive effect of CS-A 
on precursors of suppressor T  cells. 
Of much greater interest to us was the associated augmentation of DTH skin 
reactions and concomitant suppression of antibody responses. A similar reciprocal 
relationship between humoral and DTH responses produced by cyclophospha- 
mide treatment is  explained by Diamantstein  et al.  (28),  in  which various T 
lymphocyte subpopulations, involved in mediation and regulation of DTH and 
of humoral responses, differ in their sensitivity to cyclophosphamide. The precise 
mechanism of the inverse action of CS-A on humoral and cell-mediated immune 
responses in the present study is unclear, but it is conceivable that an inhibitory 
effect of CS-A on a population of suppressor T cells is at least in part responsible. 
These results further indicate that antibody is not the sole regulatory factor and 
that cell-mediated immune responses measured by DTH skin reactions play an 
important role in influencing the course of the disease. 
In the third experiment, we investigated the effect of CS-A on the established 
disease. CS-A also showed an enhancing effect on the established disease and this 
enhancement was accompanied by an augmentation of DTH skin reactions and 
unaffected antibody responses.  Although the enhancing effect of CS-A in  the 
present experiment and in its preclinical use was rapidly reversible upon cessation 
of its administration, we are concerned by the therapeutic use of CS-A since the 
clinical  relevance of this  finding  is  that  CS-A  may not  be  effective for  the 
treatment of human arthritides. In fact, the studies by Graf et al. (29) indicate 
that the effect of CS-A on rheumatoid and psoriatic arthritis is not satisfactory. 
In conclusion, CS-A can either suppress or enhance the clinical symptoms of 
collagen arthritis in rats depending on the treatment regimen. The paradoxical 
effects of CS-A  on  collagen arthritis  might be  caused by the altering of the 
sensitive balance of the two regulatory subpopulations of T  lymphocytes, helper 
and  suppressor  cells.  The  results also  suggest  that  cell-mediated immune re- 
sponses may play an important role in influencing the course of the disease.  If 
further experiments in  other situations  bear these out,  CS-A  will  provide an 
extremely useful tool for the investigation of functionally different T  cell sub- 
populations. 
Summary 
The effect of the immunosuppressive agent cyclosporin A (CS-A) on collagen 
arthritis in Sprague-Dawley rats is investigated. A 14-d course of CS-A treatment 
at doses of 15 mg/kg per day or more, begun on the same day as type II collagen 
immunization, suppressed the development of arthritis as well as humoral and 
delayed-type hypersensitivity (DTH)  skin  test  responses  to  type  II  collagen, 
possibly by interfering with helper T  cells. Additional studies demonstrated that 
CS-A  treatment only during  the  induction  phase  of immunity proved  to  be 
successful.  When  CS-A  treatment  was  started  only  during  the  immediately 
preclinical phase of arthritis or after the disease onset, a significant enhancement 
of the disease was obtained in a dose-dependent manner. This enhancement was 2014  EFFECTS  OF  CYCLOSPORIN  A  ON  COLLAGEN  ARTHRITIS 
accompanied  by an  augmentation  of DTH  skin  reactions,  while  antibody  re- 
sponses were either suppressed or unaffected. These results appear to be attrib- 
utable at least in part to a suppressive effect of CS-A on a population of suppressor 
T  cells, thus resulting in a T  cell-mediated helper effect. It is therefore reasonable 
to assume that the paradoxical effects of CS-A on collagen arthritis in rats might 
be caused by an altering of the sensitive balance of the two regulatory subpopu- 
lations  of T  cells.  It is also possible  that  cell-mediated immune responses  may 
play an important role in influencing the course of the disease. 
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